Main Article Content

Abstract

One of the most common crucial cancer that occur in femal is the ovarian cancer. Approximately evaluated new cases 21,550 and deaths 14,600 from ovarian cancer in the America in 2009. "Human Epidermal growth factor Receptor 1" HER2 it's once of agents stands and is a protein show higher rate of offensive in ovarian cancer. HER2 most famous protein which target in Herceptin therapy of ovarian cancer in metastatic status in case the tumor resulting of protein over expression. FISH technique used on TMA with HER2 specific probes it is the most commonly prove method had been use and have important role in analysis for HER2 status revelation and copy number changes. In this study we detected HER2 overexpression and cytogenetic analysis in ovarian cancer patients by using new technology tissue microarrays (TMA) and Fluorescence In Situ Hybridization (FISH). In tumors with low malignant potential there is no amplification also that we are found in Benign ovarian tumors. While we notice that HER2 increase in malignancies tumor, low malignant ovarian tumors and finally in benign ovarian tumors. In conclusion conceder the detecting and simultaneous quantification of HER2 overexpression gene by means of FISH assay, might enable the showing of a more precise stratification of ovarian cancer patients.

Keywords

Ovarian HER2 FISH TMA

Article Details

How to Cite
Alzeyadi, M. ., Imarah, A. A. ., Khayoon , S. Q. ., & Alhamadani, I. M. . (2020). Cytogenetic Analysis of HER2 in Ovarian Cancer Patients by Fluorescence in Situ Hybridization. European Journal of Engineering Science and Technology, 3(1), 1-7. https://doi.org/10.33422/ejest.v3i1.154